Diseases investigated in the fourth phase

Diseases investigated in the fourth phase

• 500 new ophthalmic/metabolic/neurological/cutaneous/blood/immune/bone patients who did not have known mutations from previous phases.
• 500 new ophthalmic/metabolic/neurological/cutaneous/blood/immune/bone patients who did not have known mutations from previous phases.